Toward Sex-Specific Guidelines for Cardiac Resynchronization Therapy?
Robbert Zusterzeel1,2,3, Kimberly A Selzman4, William E Sanders4
1Center for Devices and Radiological Health, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA. robbert.zusterzeel@fda.hhs.gov.
Journal of Cardiovascular Translational Research
|December 15, 2015
Summary
Cardiac resynchronization therapy (CRT) shows greater benefits in certain women subgroups, yet guidelines lag. This review highlights sex-specific CRT responses, urging guideline updates for equitable heart failure treatment.
Area of Science:
- Cardiology
- Medical Guidelines
- Sex-Specific Medicine
Background:
- Cardiac resynchronization therapy (CRT) is a key heart failure treatment.
- Women are underrepresented in CRT clinical trials (20%).
- Recent studies suggest subgroups of women benefit more from CRT than men.
Purpose of the Study:
- To review the sex-specific literature on heart failure and CRT response.
- To highlight discrepancies between current guidelines and recent findings.
- To advocate for separate CRT guideline considerations for women and men.
Main Methods:
- Literature review of CRT physiology, heart failure, and electrophysiology.
- Analysis of sex-specific outcomes and CRT benefits.
- Synthesis of current research on sex differences in CRT response.
Main Results:
- Subgroups of women demonstrate a greater benefit from CRT compared to men.
- Current professional society guidelines may not reflect optimal CRT for women due to outdated recommendations.
- Recent studies showing enhanced female benefit were published after the latest ACCF/AHA/HRS guidelines.
Conclusions:
- Existing CRT guidelines may not adequately represent the needs of all women patients.
- Sex-specific data on heart failure and CRT response necessitates guideline revision.
- Separate considerations for CRT in men and women are crucial for effective treatment.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
547
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
547
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
697
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697
01:23Cardiopulmonary Resuscitation III: AED Use
1.2K
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
1.2K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
751
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
01:29Cardiomyopathy V: Interprofessional Care
634
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
634
01:25Dysrhythmias VI: Management of Dysrhythmias
613
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
613